Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Thyroid medication recalled nationwide over potential superpotency risk

Vitruvias Therapeutics is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg, due to a potential superpotency risk that could lead to hyperthyroidism. The FDA published the announcement, and the company reports no adverse events connected to the recall. Consumers are advised not to stop medication without contacting their healthcare provider.

By Tertius News AI Desk 2 outlets · 2 articles Version 1 Coverage Aug 25–26, 2026 Published 1h ago

Nationwide Recall of Thyroid Medication

Vitruvias Therapeutics is voluntarily recalling one lot of thyroid medication distributed nationwide after testing found the tablets could be more potent than intended. The recall, announced by the U.S. Food and Drug Administration (FDA) on Monday, affects Lot 504950 of Thyroid Tablets, USP 30 mg, at the consumer level.

The Auburn, Alabama-based company initiated the recall because of the potential for the medication to be "superpotent." According to the company, taking superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, with symptoms that may include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.

Risks to Vulnerable Populations

The company highlighted that elderly patients, pregnant women, and infants face greater risks from excessive thyroid hormone levels, particularly with extended use. Excess thyroid hormone has been associated with cardiac problems in elderly patients, while overtreatment during pregnancy has been linked to premature delivery and low birth weight. In infants, overtreatment may negatively affect growth and development.

Vitruvias Therapeutics said it has not received any reports of adverse events known to be connected to the recall. The company is notifying wholesalers to stop distributing the recalled product and is arranging for its destruction.

Product Details and Distribution

The recalled product carries NDC 69680-166-00 and an expiration date of Sept. 30, 2026. The company released 3,655 units and reported that 1,955 units were sold. The affected lot was distributed nationwide to the company's direct accounts between Jan. 31, 2025, and Sept. 30, 2025.

Thyroid, USP is derived from porcine thyroid glands and contains levothyroxine and liothyronine. The medication is used to treat hypothyroidism, or an underactive thyroid.

Consumer Guidance

Patients currently taking tablets from the affected lot are advised not to stop taking the medication without first contacting their healthcare provider. Consumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or at 256-239-9373. Anyone who has experienced problems that may be connected to the medication should contact a physician or healthcare provider.

The recall is being conducted with the knowledge of the FDA. A representative for Vitruvias Therapeutics did not immediately respond to FOX Business' request for additional information.

How each outlet told it

Fox Business as of Aug 25, 2026, 9:20 PM UTC

Framing: Focuses on the recall being nationwide and the superpotency risk, without referencing any prior FDA advisory. — Neutral and informative, with added promotional elements (promos for other content) that may shift focus slightly.

Facts Included:

Vitruvias Therapeutics is recalling one lot of thyroid medication, Lot 504950 of Thyroid Tablets, USP 30 mg, at consumer level.
Recall is voluntary and due to potential for the medication to be 'superpotent'.
FDA published the company announcement Monday.
Superpotent thyroid tablets can cause hyperthyroidism with symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.
Elderly patients, pregnant women, and infants face greater risks from excessive thyroid hormone levels, particularly with extended use.
Excess thyroid hormone associated with cardiac problems in elderly; overtreatment during pregnancy associated with premature delivery and low birth weight; in infants, may negatively affect growth and development.
Vitruvias Therapeutics has not received any reports of adverse events connected to the recall.
Recalled product carries NDC 69680-166-00 and expiration date of Sept. 30, 2026.
Company released 3,655 units and reported 1,955 units sold.
Affected lot distributed nationwide to direct accounts between Jan. 31, 2025, and Sept. 30, 2025.
Thyroid, USP derived from porcine thyroid glands and contains levothyroxine and liothyronine; used to treat hypothyroidism.
Vitruvias is notifying wholesalers to stop distributing and arranging for destruction.
Patients should not stop taking medication without contacting healthcare provider.
Contact information: safety@vitruvias.com or 256-239-9373.
Anyone who experienced problems should contact physician or healthcare provider.
Recall conducted with knowledge of the FDA.
A representative for Vitruvias Therapeutics did not immediately respond to FOX Business' request for additional information.
The article also includes calls-to-action and links to other news stories, such as 'CLICK HERE TO GET FOX BUSINESS ON THE GO' and headlines about other recalls/outbreaks.

Read the source article →

New York Post as of Aug 26, 2026, 1:18 AM UTC

Framing: Emphasizes that the recall comes one month after FDA advised against similar tablets, framing the recall in a broader context of regulatory warnings. — Neutral and informative, using 'could cause' and 'may negatively affect' to convey uncertainty.

Facts Included:

Vitruvias Therapeutics is recalling one lot of thyroid medication, Lot 504950 of Thyroid Tablets, USP 30 mg, at consumer level.
Recall is voluntary and due to potential for the medication to be 'superpotent'.
FDA published the company announcement Monday.
Superpotent thyroid tablets can cause hyperthyroidism with symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.
Elderly patients, pregnant women, and infants face greater risks from excessive thyroid hormone levels, particularly with extended use.
Excess thyroid hormone associated with cardiac problems in elderly; overtreatment during pregnancy associated with premature delivery and low birth weight; in infants, may negatively affect growth and development.
Vitruvias Therapeutics has not received any reports of adverse events connected to the recall.
Recalled product carries NDC 69680-166-00 and expiration date of Sept. 30, 2026.
Company released 3,655 units and reported 1,955 units sold.
Affected lot distributed nationwide to direct accounts between Jan. 31, 2025, and Sept. 30, 2025.
Thyroid, USP derived from porcine thyroid glands and contains levothyroxine and liothyronine; used to treat hypothyroidism.
Vitruvias is notifying wholesalers to stop distributing and arranging for destruction.
Patients should not stop taking medication without contacting healthcare provider.
Contact information: safety@vitruvias.com or 256-239-9373.
Anyone who experienced problems should contact physician or healthcare provider.
Recall conducted with knowledge of the FDA.
A representative for Vitruvias Therapeutics did not immediately respond to FOX Business' request for additional information.

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimVitruvias Therapeutics is recalling one lot of thyroid medication, Lot 504950 of Thyroid Tablets, USP 30 mg, at the consumer level.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe recall is voluntary and due to the potential for the medication to be 'superpotent'.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe FDA published the company announcement Monday.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimSuperpotent thyroid tablets can cause hyperthyroidism, with symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimElderly patients, pregnant women, and infants face greater risks from excessive thyroid hormone levels, particularly with extended use.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimExcess thyroid hormone has been associated with cardiac problems in elderly patients; overtreatment during pregnancy has been associated with premature delivery and low birth weight; in infants, overtreatment may negatively affect growth and development.	ConfidenceMedium	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimVitruvias Therapeutics has not received any reports of adverse events known to be connected to the recall.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe recalled product carries NDC 69680-166-00 and an expiration date of Sept. 30, 2026.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe company released 3,655 units and reported 1,955 units sold.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe affected lot was distributed nationwide to the company's direct accounts between Jan. 31, 2025, and Sept. 30, 2025.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThyroid, USP is derived from porcine thyroid glands and contains levothyroxine and liothyronine, and is used to treat hypothyroidism.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimVitruvias Therapeutics is notifying wholesalers to stop distributing the recalled product and arranging for its destruction.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimPatients currently taking tablets from the affected lot should not stop taking the medication without first contacting their healthcare provider.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimConsumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or at 256-239-9373.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimAnyone who has experienced problems that may be connected to the medication should contact a physician or healthcare provider.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimThe recall is being conducted with the knowledge of the FDA.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC
ClaimA representative for Vitruvias Therapeutics did not immediately respond to FOX Business' request for additional information.	ConfidenceHigh	StatusMulti-source (2 outlets) via New York Post as of Aug 26, 2026, 1:18 AM UTC, Fox Business as of Aug 25, 2026, 9:20 PM UTC

Transparency & Audit Trail

2 outlets · 2 articles consulted: Fox Business, New York Post 17 claims extracted Version 1 Written 2026-08-26